drugset / Trial / NCT00775203

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

NCT00775203

Phase 3 Completed 412 enrolled Labopharm Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).

Timeline

Start
2007-06
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Trazodone Small molecule 150 mg
Subject Trazodone Small molecule 375 mg